Friedlaender, Alex
Perol, Maurice
Banna, Giuseppe Luigi
Parikh, Kaushal
Addeo, Alfredo
Funding for this research was provided by:
University of Geneva
Article History
Received: 25 August 2023
Accepted: 17 January 2024
First Online: 12 February 2024
Declarations
:
: Not applicable.
: Not applicable.
: The Authors declare the following competing interests.A.F. reports consulting fees from Amgen, AstraZeneca, Roche, Astellas, Takeda, Bristol-Myers Squibb, Merck Sharpe Dohme, Pfizer, Merck, Novartis and Janssen. MP reports no conflicts of interest. GLB reports personal fees from AstraZeneca, Astellas, travel and conference expenses from Janssen, KP reports advisory board fees from Guardant Health and Jazz Pharmaceuticals. AA reports advisory board fees from Merck Sharpe Dohme, Roche, Takeda, Pfizer, Bristol-Myers Squibb, AstraZeneca, Eli-Lilly; speaker’s bureau fees from Eli-Lilly, AstraZeneca, Amgen.